The objective of the study is to collect ‘real-world’ safety, efficacy, health economics, and patient-reported quality-of-life data in over 700 patients with PAD treated with SELUTION SLR.
PRESTIGE* is a prospective, single-center, physician-initiated clinical study, run at the Singapore General Hospital (SGH) by Associate Professor Tze Tec Chong and Dr. Tjun Yip Tang.
The PRISTINE registry is a follow up to the encouraging results seen in the PRESTIGE clinical trial (Below The Knee, Chronic Limb Threatening Ischemia) at 6 months.
The SELUTION SLR™ Study involves up to 132 patients across a number of centres in Japan. Its objective is to assess the safety and efficacy of SELUTION SLR for the treatment of lesions of superficial femoral arteries and/or popliteal arteries.
MedAlliance Announces Enrollment of the 1st Patient In Its SELUTION SLR™ 014 DEB Study for the treatment of In-Stent Restenosis
The objectives of this prospective, randomized, single-blind multicenter study are to demonstrate the safety and efficacy o SELUTION SLR™ 014 DEB n the treatment of ISR with either drug-eluting or bare-metal stents. The study will support the submission for FDA approval.
SELUTION SLR Sirolimus Drug Eluting Balloon for Endovascular Applications Receives CE Approval: Award Supported by 2 Year Results from the SELUTION SLR First-in-Human Study Involving 50 Patients
This award was supported by two-year results from the SELUTION SLR First-in-Human study, involving 50 patients enrolled across four German centres.